S-1: Invizyne Technologies Files for IPO, Aiming to Revolutionize Biomanufacturing

Invizyne Technologies, a biomanufacturing company, has filed an S-1 registration statement for an initial public offering (IPO) to advance its SimplePath platform and revolutionize the production of chemicals.

Summary

• Invizyne Technologies has filed an S-1 registration statement for an IPO.
• The company aims to redefine biomanufacturing using its SimplePath platform, which leverages cell-free, multi-step enzyme-based systems.
• Invizyne intends to offer 4,300,000 shares of common stock at an estimated price of $4.00 per share, seeking to raise approximately $17.2 million.
• The company's SimplePath platform is presented as an alternative to chemical synthesis, natural extraction, and synthetic biology for producing chemicals.
• Invizyne has focused its efforts on two platform areas: cannabinoids and biofuels.
• The company has received $12,739,318 in grants to date from government and non-government sources.
• MDB Capital Holdings, LLC, the majority holder of Invizyne's Common Stock, beneficially holds 8,277,851 shares, representing 62.89% of the outstanding shares prior to the offering.
• Public Ventures, LLC, a wholly-owned subsidiary of MDB, is acting as the underwriter for the IPO, creating a conflict of interest that necessitates a qualified independent underwriter, Digital Offering LLC.
• The company intends to apply to list its Common Stock on The Nasdaq Capital Market under the symbol IZTC.
• Invizyne acknowledges it is an emerging growth company and will take advantage of reduced disclosure obligations.
• The company has a limited operating history and has not generated any revenues to date.
• The company anticipates needing additional funding in the future to fully develop its business plan, with the funds from this offering expected to fund operations for 12 to 24 months.
• The company's independent accountants have issued their report with a going concern statement.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While it highlights the potential of Invizyne's technology and its commitment to innovation, it also acknowledges the company's limited operating history, lack of revenue, and the need for additional funding. The going concern statement from the independent accountants further tempers the positive aspects.

Positives

• The SimplePath platform has the potential to revolutionize biomanufacturing and offer a sustainable alternative to traditional methods.
• The company has secured substantial US government grants, particularly from the Department of Energy (DOE) and the National Institutes of Health (NIH).
• The company has a strong intellectual property portfolio, including patents and patent applications.
• The company is targeting high-growth markets such as cannabinoids and biofuels.

Negatives

• The company has a limited operating history and has not generated any revenues to date.
• The company anticipates needing additional funding in the future to fully develop its business plan, with the funds from this offering expected to fund operations for 12 to 24 months.
• The company's independent accountants have issued their report with a going concern statement.
• The IPO is underwritten by Public Ventures, LLC, a subsidiary of MDB Capital Holdings, LLC, creating a conflict of interest.
• The company is highly dependent on retaining its scientific staff and being able to hire additional scientific and related managerial staff.
• The company does not have any sales, marketing, manufacturing and distribution capabilities or arrangements, and will need to create these as it moves towards commercialization of its products.

Risks

• The company has a limited operating history and has not generated any revenues to date.
• The company anticipates needing additional funding in the future to fully develop its business plan, with the funds from this offering expected to fund operations for 12 to 24 months.
• The company's independent accountants have issued their report with a going concern statement.
• The synthetic biological platform being developed by the Company may not be able to develop a pipeline of commercial products, and commercial products may not be adopted by clients in the intended markets due to the novelty and complexity of the technologies involved.
• The company does not have any sales, marketing, manufacturing and distribution capabilities or arrangements, and will need to create these as it moves towards commercialization of its products.
• There may be regulatory hurdles that will have to be satisfied before the bio-synthesized compounds, which are the end products of the platform, can be marketed and commercially used.
• The company is highly dependent on retaining its scientific staff and being able to hire additional scientific and related managerial staff.
• Although the company has successfully achieved the production of products in the laboratory, conditions in the laboratory setting may not be reproduced in a commercial setting.
• The company's systems rely on the need for purified enzymes and co-factors for the conversions of input feedstock into final products.
• Currently, the company's business is highly dependent on a small number of products, which are based on its principal technology.
• Collaborations of various sorts, by our partner companies, such as with respect to research, testing, manufacturing and distribution, will be important to our business.
• There is extensive competition that the company will face from legacy processes and other companies seeking to use bio-manufacturing and enzyme pathways to develop products alternative to traditional chemicals and petroleum based products.
• If the company is unable to protect the intellectual property used in its technology platform and products, others may be able to copy our innovations which may impair our ability to compete effectively in our markets.
• The company will incur increased costs as a result of operating as a public company, and our board of directors will be required to devote substantial time to oversight of new compliance requirements and corporate governance practices.
• The company is an emerging growth company under the JOBS Act and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our Common Stock less attractive to investors.
• Certain recent initial public offerings of companies with relatively small public floats have experienced extreme volatility that was seemingly unrelated to the underlying performance of the company.
• Concentration of ownership among our existing executive officers, directors and significant stockholders may prevent new investors from influencing significant corporate decisions.
• The price of the company's Common Stock may have little or no relationship to the historical sales price of our capital stock in our private placement transactions to date.
• The company's failure to meet the continued listing requirements of Nasdaq could result in a delisting of our Common Stock.
• The company may allocate the net proceeds from this offering in ways that differ from the estimates discussed in the section titled Use of Proceeds and with which you may not agree, and if we do not use those proceeds effectively your investment could be harmed.
• You will experience immediate dilution in the book value per share of the Common Stock you purchase.

Future Outlook

The company plans to use the net proceeds from the IPO to expand production capabilities, increase staff, expand business development, sales, and marketing, expand the R&D and technology platform, for working capital and other general purposes, to pay commissions, IPO fees, and debt repayment.

Industry Context

The document highlights the growing biobased industry and the shift towards sustainable chemical production. It positions Invizyne's SimplePath platform as a potential solution to the limitations of traditional chemical synthesis, natural extraction, and synthetic biology.

Comparison to Industry Standards

• The document mentions competitors like Debut Biotech and Solugen Inc. in the cell-free enzymatic systems space, but notes their processes appear to use simple one to two step pathways.
• Codexis, Inc. is mentioned for its partnership with Tate&Lyle and Merck & Co., Inc. on different, highly specific projects that use multi enzyme pathways, which demonstrate that enzymatic Islatravir synthesis does illustrate the potential for complex or longer enzyme cascades but their principal mission diverges from the enzymatic manufacturing of more general chemicals.
• The document also acknowledges competition from companies focusing on enzyme engineering, such as Codexis, Inc., Allozymes Pte Ltd. (Singapore), Enzymit Ltd. (Israel and US), Zymtronix Catalytic Systems, Inc., Arzeda Corp. and Quantumzyme LLP (India).
• In the biofuels sector, the document notes competition from companies like Valero Energy Corporation, ADM Corporation and Cargill Company and Gevo, Inc. and Butamax Advanced Biofuels LLC that focus on ethanol technologies.
• The document claims that SimplePath for isobutanol outperforms the Synbio solution of using engineered yeast cells by at least 2-fold, and titers by over 2.5-fold, based on current knowledge.
• The document also claims that SimplePath for isobutanol can ultimately produce isobutanol at greater than 3-fold the rate and nearly double the concentration of conventional ethanol processes, with greater than 95% yield.

Management Changes

Legal Proceedings

• The company is not currently subject to any material legal proceedings.

Related Party Transactions

• During 2023, MDB Capital Holdings, LLC provided the financial services of its chief financial officer to the Company.
• The value of these services was determined to be $95,000, which was charged to operations.
• The amount remains unpaid as of September 30, 2023.

Stakeholder Impact

• Shareholders will experience immediate dilution in the book value per share of the Common Stock they purchase.
• Employees may benefit from the company's growth and expansion plans, including potential hiring and increased compensation.
• Customers may benefit from the company's innovative biomanufacturing platform and its potential to produce sustainable, high-quality chemical products.
• Suppliers may benefit from increased demand for raw materials and services as the company expands its operations.
• Creditors may be impacted by the company's financial performance and its ability to repay its debts.

Next Steps

• The company intends to apply to list its Common Stock on The Nasdaq Capital Market under the symbol IZTC.
• The company plans to use the net proceeds from the IPO to expand production capabilities, increase staff, expand business development, sales, and marketing, expand the R&D and technology platform, for working capital and other general purposes, to pay commissions, IPO fees, and debt repayment.

Key Dates

Keywords

biomanufacturing, SimplePath, IPO, cannabinoids, biofuels, enzymes, synthetic biology, MDB Capital Holdings, Public Ventures, emerging growth company